Sun Pharma ’s Phase III trials of Baclofen GRS fail to meet primary endpoint

India-based Sun Pharma Advanced Research (SPARC) has reported top-line results from two Phase III clinical trials of Baclofen GRS to treat spasticity in patients suffering from multiple sclerosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news